The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [11]
Experimental — accuracy not yet measured
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Shah, S. P., Köbel, M., Senz, J., Morin, R. D., Clarke, B. A., Wiegand, K. C., Leung, G., Zayed, A., Mehl, E., Kalloger, S. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902542 · Cited by 768
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Self-citationCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Cited by
Items 101–200 of 1,006
Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy
Ottis, P., & Crews, C. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.6b01068 · Cited by 220
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
Faust, T. B., Yoon, H., Nowak, R. P., Donovan, K. A., Li, Z., Cai, Q., Eleuteri, N. A., Zhang, T., Gray, N. S., & Fischer, E. S. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0378-3 · Cited by 218
Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
Simonetta, K. R., Taygerly, J., Boyle, K., Basham, S. E., Padovani, C., Lou, Y., Cummins, T. J., Yung, S. L., von Soly, S. K., Kayser, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09358-9 · Cited by 217
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215
“ular glues can target transcription factors and splicing factors, by recognizing either relatively flat surfaces or disordered regions of these proteins (Han et al., 2017; Krönke et al., 2014; Lu et al., 2014; Tan et al., 2007).”
BackgroundZhu, Y. X., Braggio, E., Shi, C.-X., Kortuem, K. M., Bruins, L. A., Schmidt, J. E., Chang, X.-B., Langlais, P., Luo, M., Jedlowski, P., et al. (2014) · Blood · doi:10.1182/blood-2014-02-557819 · Cited by 213
The novel mechanism of lenalidomide activity
Fink, E. C., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-07-567958 · Cited by 213
Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome
Cavadini, S., Fischer, E. S., Bunker, R. D., Potenza, A., Lingaraju, G. M., Goldie, K. N., Mohamed, W. I., Faty, M., Petzold, G., Beckwith, R. E. J., et al. (2016) · Nature · doi:10.1038/nature17416 · Cited by 213
Immunotherapy of multiple myeloma
Minnie, S. A., & Hill, G. R. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129205 · Cited by 210
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 209
The Ubiquitin–Proteasome System in Immune Cells
Çetin, G., Klafack, S., Studencka-Turski, M., Krüger, E., & Ebstein, F. (2021) · Biomolecules · doi:10.3390/biom11010060 · Cited by 209
Targeted Protein Degradation by Small Molecules
Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103507 · Cited by 207
“Ikaros family members activate the IRF4 locus, a gene to which myeloma cells are addicted (33, 34), although not all IMiDsensitive cell lines have decreased IRF4 levels, indicating IRF4 might not be necessary for this cytotoxicity (30).”
BackgroundHagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., et al. (2015) · Blood · doi:10.1182/blood-2015-02-628669 · Cited by 203
Self-citationYee, A. J., Bensinger, W. I., Supko, J. G., Voorhees, P. M., Berdeja, J. G., Richardson, P. G., Libby, E. N., Wallace, E. E., Birrer, N. E., Burke, J. N., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30375-8 · Cited by 203
Chasing molecular glue degraders: screening approaches
Domostegui, A., Nieto-Barrado, L., Perez-Lopez, C., & Mayor-Ruiz, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00197g · Cited by 200
Rubenstein, J. L., Geng, H., Fraser, E. J., Formaker, P., Chen, L., Sharma, J., Killea, P., Choi, K., Ventura, J., Kurhanewicz, J., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017014845 · Cited by 199
Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress
Neganova, M. E., Klochkov, S. G., Aleksandrova, Y. R., & Aliev, G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.015 · Cited by 197
Gough, S. M., Flanagan, J. J., Teh, J., Andreoli, M., Rousseau, E., Pannone, M., Bookbinder, M., Willard, R., Davenport, K., Bortolon, E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3465 · Cited by 196
Proximity-Based Modalities for Biology and Medicine
Liu, X., & Ciulli, A. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00395 · Cited by 196
The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron
Ichikawa, S., Flaxman, H. A., Xu, W., Vallavoju, N., Lloyd, H. C., Wang, B., Shen, D., Pratt, M. R., & Woo, C. M. (2022) · Nature · doi:10.1038/s41586-022-05333-5 · Cited by 195
Yang, J., Li, Y., Aguilar, A., Liu, Z., Yang, C.-Y., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00846 · Cited by 190
Development of the first small molecule histone deacetylase 6 (HDAC6) degraders
Yang, K., Song, Y., Xie, H., Wu, H., Wu, Y.-T., Leisten, E. D., & Tang, W. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.05.057 · Cited by 190
Ahn, G., Riley, N. M., Kamber, R. A., Wisnovsky, S., Moncayo von Hase, S., Bassik, M. C., Banik, S. M., & Bertozzi, C. R. (2023) · Science · doi:10.1126/science.adf6249 · Cited by 189
Molecular glues for protein-protein interactions: Progressing toward a new dream
Konstantinidou, M., & Arkin, M. R. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.04.002 · Cited by 187
PROTACs: A novel strategy for cancer therapy
Liu, J., Ma, J., Liu, Y., Xia, J., Li, Y., Wang, Z. P., & Wei, W. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.006 · Cited by 186
Harnessing the Power of Proteolysis for Targeted Protein Inactivation
Verma, R., Mohl, D., & Deshaies, R. J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.010 · Cited by 185
Rational Chemical Design of Molecular Glue Degraders
Toriki, E. S., Papatzimas, J. W., Nishikawa, K., Dovala, D., Frank, A. O., Hesse, M. J., Dankova, D., Song, J.-G., Bruce-Smythe, M., Struble, H., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01317 · Cited by 184
Eichner, R., Heider, M., Fernández-Sáiz, V., van Bebber, F., Garz, A.-K., Lemeer, S., Rudelius, M., Targosz, B.-S., Jacobs, L., Knorn, A.-M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4128 · Cited by 183
Du, X., Volkov, O. A., Czerwinski, R. M., Tan, H., Huerta, C., Morton, E. R., Rizzi, J. P., Wehn, P. M., Xu, R., Nijhawan, D., et al. (2019) · Structure · doi:10.1016/j.str.2019.10.005 · Cited by 181
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity
Wu, H., Yang, K., Zhang, Z., Leisten, E. D., Li, Z., Xie, H., Liu, J., Smith, K. A., Novakova, Z., Barinka, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00516 · Cited by 180
Cancer Therapy–Associated Thrombosis
Grover, S. P., Hisada, Y. M., Kasthuri, R. S., Reeves, B. N., & Mackman, N. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.314378 · Cited by 180
Targeted protein degradation as a powerful research tool in basic biology and drug target discovery
Wu, T., Yoon, H., Xiong, Y., Dixon-Clarke, S. E., Nowak, R. P., & Fischer, E. S. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0438-0 · Cited by 180
Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation
Wurz, R. P., Rui, H., Dellamaggiore, K., Ghimire-Rijal, S., Choi, K., Smither, K., Amegadzie, A., Chen, N., Li, X., Banerjee, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39904-5 · Cited by 146
Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs
Wang, Y., Dix, M. M., Bianco, G., Remsberg, J. R., Lee, H.-Y., Kalocsay, M., Gygi, S. P., Forli, S., Vite, G., Lawrence, R. M., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-019-0351-5 · Cited by 179
From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation
Oleinikovas, V., Gainza, P., Ryckmans, T., Fasching, B., & Thomä, N. H. (2024) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022123-104147 · Cited by 178
Van Nguyen, T., Lee, J. E., Sweredoski, M. J., Yang, S.-J., Jeon, S.-J., Harrison, J. S., Yim, J.-H., Lee, S. G., Handa, H., Kuhlman, B., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.032 · Cited by 177
“Recent studies have revealed that binding of IMiDs to CRBN promotes recruitment of neosubstrates, including Ikaros (IKZF1), Aiolos (IKZF3) (Kronke et al., 2014; Lu et al., 2014) and casein kinase 1A1 (CK1α) (Kronke et al., 2015) to CRL4CRBN, leading to their increased ubiquitylation and proteasome-dependent degradatio…”
InfluentialTargeted degradation of the enhancer lysine acetyltransferases CBP and p300
Vannam, R., Sayilgan, J., Ojeda, S., Karakyriakou, B., Hu, E., Kreuzer, J., Morris, R., Herrera Lopez, X. I., Rai, S., Haas, W., et al. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.12.004 · Cited by 177
Self-citationIshoey, M., Chorn, S., Singh, N., Jaeger, M. G., Brand, M., Paulk, J., Bauer, S., Erb, M. A., Parapatics, K., Müller, A. C., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00969 · Cited by 177
Self-citationpSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
An, J., Ponthier, C. M., Sack, R., Seebacher, J., Stadler, M. B., Donovan, K. A., & Fischer, E. S. (2017) · Nature Communications · doi:10.1038/ncomms15398 · Cited by 176
PROTACs to address the challenges facing small molecule inhibitors
Martín-Acosta, P., & Xiao, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112993 · Cited by 172
Haven't got a glue: Protein surface variation for the design of molecular glue degraders
Kozicka, Z., & Thomä, N. H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.009 · Cited by 170
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dobrovolsky, D., Wang, E. S., Morrow, S., Leahy, C., Faust, T., Nowak, R. P., Donovan, K. A., Yang, G., Li, Z., Fischer, E. S., et al. (2019) · Blood · doi:10.1182/blood-2018-07-862953 · Cited by 169
Camicia, R., Winkler, H. C., & Hassa, P. O. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0474-2 · Cited by 169
Progress and Paradigms in Multiple Myeloma
Anderson, K. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0625 · Cited by 169
Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy
Bonazzi, S., d’Hennezel, E., Beckwith, R. E. J., Xu, L., Fazal, A., Magracheva, A., Ramesh, R., Cernijenko, A., Antonakos, B., Bhang, H.-E. C., et al. (2023) · Cell Chemical Biology · doi:10.1016/j.chembiol.2023.02.005 · Cited by 167
Self-citationEmerging degrader technologies engaging lysosomal pathways
Ding, Y., Xing, D., Fei, Y., & Lu, B. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00624c · Cited by 170
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 163
E3 ligase ligand chemistries: from building blocks to protein degraders
Sosič, I., Bricelj, A., & Steinebach, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00148a · Cited by 163
AirID, a novel proximity biotinylation enzyme, for analysis of protein–protein interactions
Kido, K., Yamanaka, S., Nakano, S., Motani, K., Shinohara, S., Nozawa, A., Kosako, H., Ito, S., & Sawasaki, T. (2020) · eLife · doi:10.7554/elife.54983 · Cited by 163
From Discovery to Bedside: Targeting the Ubiquitin System
Wertz, I. E., & Wang, X. (2018) · Cell chemical biology · doi:10.1016/j.chembiol.2018.10.022 · Cited by 166
Developing degraders: principles and perspectives on design and chemical space
Maple, H. J., Clayden, N., Baron, A., Stacey, C., & Felix, R. (2019) · MedChemComm · doi:10.1039/c9md00272c · Cited by 154
Deshaies, R. J. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1887 · Cited by 162
Widespread intronic polyadenylation diversifies immune cell transcriptomes
Singh, I., Lee, S.-H., Sperling, A. S., Samur, M. K., Tai, Y.-T., Fulciniti, M., Munshi, N. C., Mayr, C., & Leslie, C. S. (2018) · Nature Communications · doi:10.1038/s41467-018-04112-z · Cited by 156
Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer
Kaelin, W. G. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162480 · Cited by 161
Self-citationRelapsed refractory multiple myeloma: a comprehensive overview
Bazarbachi, A. H., Al Hamed, R., Malard, F., Harousseau, J.-L., & Mohty, M. (2019) · Leukemia · doi:10.1038/s41375-019-0561-2 · Cited by 160
Homo-PROTACs for the Chemical Knockdown of Cereblon
Steinebach, C., Lindner, S., Udeshi, N. D., Mani, D. C., Kehm, H., Köpff, S., Carr, S. A., Gütschow, M., & Krönke, J. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00693 · Cited by 155
Hansen, J. D., Correa, M., Alexander, M., Nagy, M., Huang, D., Sapienza, J., Lu, G., LeBrun, L. A., Cathers, B. E., Zhang, W., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01489 · Cited by 159
Self-citationDavis, M. I., Pragani, R., Fox, J. T., Shen, M., Parmar, K., Gaudiano, E. F., Liu, L., Tanega, C., McGee, L., Hall, M. D., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.738567 · Cited by 159
Targeted protein degradation: current and future challenges
Hanzl, A., & Winter, G. E. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.012 · Cited by 149
Yamamoto, J., Ito, T., Yamaguchi, Y., & Handa, H. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00116k · Cited by 158
The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia
Marke, R., van Leeuwen, F. N., & Scheijen, B. (2018) · Haematologica · doi:10.3324/haematol.2017.185603 · Cited by 158
Template-assisted covalent modification underlies activity of covalent molecular glues
Li, Y.-D., Ma, M. W., Hassan, M. M., Hunkeler, M., Teng, M., Puvar, K., Rutter, J. C., Lumpkin, R. J., Sandoval, B., Jin, C. Y., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01668-4 · Cited by 143
Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation
Kannt, A., & Đikić, I. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.007 · Cited by 142
Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds
Würth, R., Thellung, S., Bajetto, A., Mazzanti, M., Florio, T., & Barbieri, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.017 · Cited by 165
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
Barwick, B. G., Neri, P., Bahlis, N. J., Nooka, A. K., Dhodapkar, M. V., Jaye, D. L., Hofmeister, C. C., Kaufman, J. L., Gupta, V. A., Auclair, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09555-6 · Cited by 146
An E3 ligase guide to the galaxy of small-molecule-induced protein degradation
Jevtić, P., Haakonsen, D. L., & Rapé, M. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.002 · Cited by 143
Role of LFA-1 and ICAM-1 in Cancer
Reina, M., & Espel, E. (2017) · Cancers · doi:10.3390/cancers9110153 · Cited by 159
Steinebach, C., Ng, Y. L. D., Sosič, I., Lee, C.-S., Chen, S., Lindner, S., Vu, L. P., Bricelj, A., Haschemi, R., Monschke, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc00167h · Cited by 148
Altered RNA Processing in Cancer Pathogenesis and Therapy
Obeng, E. A., Stewart, C., & Abdel-Wahab, O. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0399 · Cited by 139
Proteolysis-targeting chimeras with reduced off-targets
Nguyen, T. M., Sreekanth, V., Deb, A., Kokkonda, P., Tiwari, P. K., Donovan, K. A., Shoba, V., Chaudhary, S. K., Mercer, J. A. M., Lai, S., et al. (2024) · Nature Chemistry · doi:10.1038/s41557-023-01379-8 · Cited by 139
Multiple myeloma: the (r)evolution of current therapy and a glance into future
Gullà, A., & Anderson, K. C. (2020) · Haematologica · doi:10.3324/haematol.2020.247015 · Cited by 154
Bauer, D. E., & Orkin, S. H. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.08.001 · Cited by 143
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back
Bianchi, G., & Anderson, K. C. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21252 · Cited by 131
Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds
Lagrue, K., Carisey, A., Morgan, D. J., Chopra, R., & Davis, D. M. (2015) · Blood · doi:10.1182/blood-2015-01-625004 · Cited by 132
Collins, I., Wang, H., Caldwell, J. J., & Chopra, R. (2017) · Biochemical Journal · doi:10.1042/bcj20160762 · Cited by 137
Polizzotto, M. N., Uldrick, T. S., Wyvill, K. M., Aleman, K., Peer, C. J., Bevans, M., Sereti, I., Maldarelli, F., Whitby, D., Marshall, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.3812 · Cited by 138
Cowan, A. D., & Ciulli, A. (2022) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-032620-104421 · Cited by 130
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137
Targeting MYC in multiple myeloma
Jovanović, K., Roche‐Lestienne, C., Ghobrial, I. M., Facon, T. T. F., Quesnel, B., & Manier, S. (2018) · Leukemia · doi:10.1038/s41375-018-0036-x · Cited by 142
Structural basis of thalidomide enantiomer binding to cereblon
Mori, T., Ito, T., Liu, S., Ando, H., Sakamoto, S., Yamaguchi, Y., Tokunaga, E., Shibata, N., Handa, H., & Hakoshima, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-19202-7 · Cited by 128
Oakley, J. V., Buksh, B. F., Fernández, D. F., Oblinsky, D. G., Seath, C. P., Geri, J. B., Scholes, G. D., & MacMillan, D. W. C. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203027119 · Cited by 124
Sehgal, K., Das, R., Zhang, L., Verma, R., Deng, Y., Kocoglu, M., Vasquez, J., Koduru, S., Ren, Y., Wang, M., et al. (2015) · Blood · doi:10.1182/blood-2014-11-611426 · Cited by 132
p63 is a cereblon substrate involved in thalidomide teratogenicity
Asatsuma-Okumura, T., Ando, H., De Simone, M., Yamamoto, J., Sato, T., Shimizu, N., Asakawa, K., Yamaguchi, Y., Ito, T., Guerrini, L., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0366-7 · Cited by 134
Assi, R. E., Kantarjian, H. M., Kadia, T. M., Pemmaraju, N., Jabbour, E. J., Jain, N., Daver, N. G., Estrov, Z. E., Uehara, T., Owa, T., et al. (2018) · Cancer · doi:10.1002/cncr.31398 · Cited by 155
Ho, M., Kavanagh, E. L., Dunne, L., Dowling, P., Zhang, L., Lindsay, S., Bazou, D., Goh, C. Y., Hanley, C., Bianchi, G., et al. (2019) · Cancers · doi:10.3390/cancers11010066 · Cited by 143
Tumor microenvironment (TME)-driven immune suppression in B cell malignancy
Nicholas, N. S., Apollonio, B., & Ramsay, A. G. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.11.003 · Cited by 143
Ligandability of E3 Ligases for Targeted Protein Degradation Applications
Belcher, B. P., Ward, C. C., & Nomura, D. K. (2023) · Biochemistry · doi:10.1021/acs.biochem.1c00464 · Cited by 132
Chen, H., Liu, J., Kaniskan, H. Ü., Wei, W., & Jin, J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00901 · Cited by 118
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131
Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies
Dahl, M., Daugaard, I., Andersen, M. S., Hansen, T. B., Grønbæk, K., Kjems, J., & Kristensen, L. S. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0108-6 · Cited by 134
The state of the art of PROTAC technologies for drug discovery
Wang, C., Zheng, C., Wang, H., Zhang, L., Liu, Z., & Xu, P. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114290 · Cited by 115
ROBBINS, D. W., Noviski, M., Tan, Y. S., Könst, Z. A., Kelly, A., Auger, P., Brathaban, N., Cass, R. T., Chan, M. L., Cherala, G., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01007 · Cited by 131
How Thalidomide Works Against Cancer
Stewart, A. K. (2014) · Science · doi:10.1126/science.1249543 · Cited by 124
Targeted protein degradation and the enzymology of degraders
Fisher, S. L., & Phillips, A. J. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.05.004 · Cited by 126
Molecular mechanisms of thalidomide and its derivatives
Ito, T., & Handa, H. (2020) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.96.016 · Cited by 134
A bibliometric analysis of PROTAC from 2001 to 2021
Li, D., Yu, D., Li, Y., & Yang, R. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114838 · Cited by 134
Defining molecular glues with a dual-nanobody cannabidiol sensor
Cao, S., Kang, S., Mao, H., Yao, J., Gu, L., & Zheng, N. (2022) · Nature Communications · doi:10.1038/s41467-022-28507-1 · Cited by 125
Sievers, Q. L., Gasser, J. A., Cowley, G. S., Fischer, E. S., & Ebert, B. L. (2018) · Blood · doi:10.1182/blood-2018-01-821769 · Cited by 124
Acute pharmacological degradation of Helios destabilizes regulatory T cells
Wang, E. S., Verano, A. L., Nowak, R. P., Yuan, J. C., Donovan, K. A., Eleuteri, N. A., Yue, H., Ngo, K. H., Lizotte, P. H., Gokhale, P. C., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00802-w · Cited by 124
Manumycin polyketides act as molecular glues between UBR7 and P53
Isobe, Y., Okumura, M., McGregor, L. M., Brittain, S. M., Jones, M. D., Liang, X., White, R., Forrester, W., McKenna, J. M., Tallarico, J. A., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0557-2 · Cited by 124
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Kelm, J. M., Pandey, D. S., Malin, E., Kansou, H., Arora, S., Kumar, R., & Gavande, N. S. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01707-5 · Cited by 110
Metadata
- Authors
- Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 305-309
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4070318
- OpenAlex
- W2068412287
- Semantic Scholar
- 78bec298ec2a26703ac77b2d1a6e38c4778689df
- Cited by
- 1,583
- References
- 35
- Citations by year
- 2026: 113 · 2025: 123 · 2024: 152 · 2023: 136 · 2022: 149 · 2021: 179 · 2020: 167 · 2019: 111 · 2018: 120 · 2017: 93 · 2016: 88 · 2015: 85 · 2014: 63
- FWCI
- 35.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA076120)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, cereblon, IKZF1, IKZF3, multiple myeloma, ubiquitin ligase, proteasomal degradation, teratogenicity, zebrafish, anticancer mechanism
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Multiple Myeloma, Peptide Hydrolases, Teratogens, Thalidomide, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Ikaros Transcription Factor, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.